Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Growth in Short Interest

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 9,060,000 shares, a growth of 8.8% from the March 15th total of 8,330,000 shares. Based on an average daily volume of 752,000 shares, the days-to-cover ratio is presently 12.0 days.

Kymera Therapeutics Price Performance

KYMR traded down $1.19 during trading on Monday, hitting $34.39. The company's stock had a trading volume of 528,658 shares, compared to its average volume of 756,858. The stock has a market cap of $2.10 billion, a PE ratio of -13.65 and a beta of 2.27. The firm's 50 day moving average price is $39.21 and its 200-day moving average price is $27.49. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.19. The business had revenue of $47.90 million during the quarter, compared to the consensus estimate of $41.94 million. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The business's revenue for the quarter was up 197.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.60) EPS. Equities analysts anticipate that Kymera Therapeutics will post -3.13 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on KYMR. Truist Financial boosted their price target on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. JPMorgan Chase & Co. upped their target price on Kymera Therapeutics from $34.00 to $47.00 and gave the company an "overweight" rating in a research note on Friday, February 23rd. Wells Fargo & Company lowered Kymera Therapeutics from an "overweight" rating to an "equal weight" rating and set a $26.00 target price on the stock. in a research note on Tuesday, December 19th. Piper Sandler upped their target price on Kymera Therapeutics from $39.00 to $56.00 and gave the company an "overweight" rating in a research note on Tuesday, February 27th. Finally, Stifel Nicolaus upped their target price on Kymera Therapeutics from $35.00 to $55.00 and gave the company a "buy" rating in a research note on Friday, February 23rd. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $39.89.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 3,934 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $41.86, for a total value of $164,677.24. Following the sale, the chief financial officer now owns 142,351 shares of the company's stock, valued at approximately $5,958,812.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Kymera Therapeutics news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $42.85, for a total value of $1,812,640.70. Following the sale, the insider now owns 4,925,812 shares of the company's stock, valued at approximately $211,071,044.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 3,934 shares of the business's stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $41.86, for a total value of $164,677.24. Following the sale, the chief financial officer now directly owns 142,351 shares in the company, valued at approximately $5,958,812.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 484,051 shares of company stock valued at $19,924,711. 16.67% of the stock is owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its holdings in shares of Kymera Therapeutics by 5.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,335,712 shares of the company's stock worth $135,848,000 after buying an additional 278,287 shares during the last quarter. BVF Inc. IL boosted its position in Kymera Therapeutics by 8.9% during the 4th quarter. BVF Inc. IL now owns 5,161,801 shares of the company's stock worth $131,419,000 after purchasing an additional 422,797 shares during the period. Vanguard Group Inc. boosted its position in Kymera Therapeutics by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company's stock worth $101,778,000 after purchasing an additional 72,351 shares during the period. State Street Corp boosted its position in Kymera Therapeutics by 67.8% during the 2nd quarter. State Street Corp now owns 3,514,438 shares of the company's stock worth $69,199,000 after purchasing an additional 1,419,877 shares during the period. Finally, BlackRock Inc. boosted its position in Kymera Therapeutics by 0.6% during the 1st quarter. BlackRock Inc. now owns 3,419,084 shares of the company's stock worth $144,698,000 after purchasing an additional 21,544 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.